- Home
- ITRM
as 12-18-2024 1:38pm EST
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
| Founded: | 2015 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 49.5M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $3.02 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Iterum Therapeutics plc News
ITRM Breaking Stock News: Dive into ITRM Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Iterum Therapeutics Shares Rise After Regaining Compliance With Nasdaq's Listing Rules
GlobeNewswire
a month ago
Iterum Therapeutics Regains Full Nasdaq Compliance
GuruFocus.com
a month ago
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
GlobeNewswire
a month ago
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Benzinga
2 months ago
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships
Pharmaceutical Technology
2 months ago
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
PR Newswire
2 months ago
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
Compare ITRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITRM Iterum Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.